Kerendia Fenerinon 20 Mg - 28 Tablets

Kerendia Finerenone 28 Tablets contains the active ingredient finerenone at a concentration of 20 mg and is used for adults with chronic kidney disease (CKD) associated with type 2 diabetes.

Benefits and Uses of Kerendia Finerenone 20 Mg

Kerendia Finerenone is used for end stage kidney disease in adults with type 2 diabetes to: 

• Help slow the decline in kidney function.

• It also helps lower the risk of death due to cardiovascular disease, non-fatal heart attacks, and hospitalization due to heart failure.

• Kerendia’s effectiveness lies in its active ingredient finerenone, which reduces the effect of certain hormones that may damage the kidneys and heart.

• It is specifically used to treat patients with stage 3 and 4 CKD who also have abnormally high levels of albumin in the urine.

Contraindications

• Should not be used with strong CYP3A4 inhibitors.

• Contraindicated in patients with adrenal gland insufficiency.

How to Use

• Use exactly as prescribed by your doctor or pharmacist.

• The maximum daily dose is one 20 mg tablet.

• Take once daily, with or without food, at the same time each day.

• Tablets can be swallowed with water. If swallowing is difficult, the tablet may be crushed and mixed with water or soft food (e.g., applesauce) and consumed immediately.

• Do not take with grapefruit juice.

• Dosage Determination:

• Dosage is determined based on kidney function as assessed by a blood test.

• Initial dose may be 10 mg or 20 mg daily.

• After 4 weeks, a follow-up blood test is required to adjust the dose or discontinue the treatment based on the results.

Side Effects

• Low sodium levels (may cause nausea, fatigue, headache, confusion, muscle weakness or cramps).

• Decreased kidney function.

• Increased uric acid in the blood.

• Low blood pressure (may cause dizziness or fainting).

• Itching.

Warnings and Precautions

• Hyperkalemia (high potassium levels):

• Kerendia may increase potassium levels, especially in patients with kidney impairment or risk factors.

• Potassium and eGFR should be checked before starting treatment.

• Do not initiate treatment if potassium levels exceed 5.0 mmol/L.

• Potassium should be monitored regularly during treatment. In some cases, close monitoring may be required.

• Breastfeeding:

• Breastfeeding is not recommended during treatment and for 24 hours after the last dose.

• Liver Impairment:

• Kerendia is contraindicated in severe liver impairment (Child-Pugh C) and potassium levels should be monitored in moderate impairment (Child-Pugh B).

Drug Interactions

• Strong CYP3A4 inhibitors:

• Do not use with Kerendia. Avoid grapefruit and grapefruit juice.

• Moderate or weak CYP3A4 inhibitors:

• Monitor potassium levels when starting or adjusting the dose. Adjust Kerendia dosage if needed.

• Strong or moderate CYP3A4 inducers:

• Concurrent use should be avoided.

Storage

• Store at a cool, dry place.

• Keep out of reach of children.

Kerendia Finerenone 20 Mg Ingredients

• Active Ingredient:

• Finerenone (20 mg per tablet).

• Other Ingredients:

• Cellulose.

• Lactose.

• Sodium.

• Coloring agents (yellow iron oxide).

• Additional ingredients for tablet core and coating.